Study of Effects of Alogliptin on Diabetic Atherosclerosis by Gray-Scale Median (GSM)
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Alogliptin (Primary)
- Indications Atherosclerosis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SPEAD-A GSM
- 28 Nov 2017 Status changed from recruiting to completed.
- 29 May 2017 Status changed from active, no longer recruiting to recruiting.
- 02 Dec 2015 New trial record